Myocardial Viability Imaging: Which Test When

Quick Answer

Viability imaging asks a single question: in a patient with ischemic LV dysfunction, is dysfunctional myocardium hibernating (viable, likely to recover with revascularization) or scarred (irreversible)? FDG-PET perfusion/metabolism is the reference standard — a perfusion–metabolism mismatch (reduced flow but preserved FDG uptake) marks hibernating myocardium. SPECT with thallium redistribution or nitrate-augmented sestamibi assesses membrane integrity/perfusion and is widely available. Cardiac MRI with late gadolinium enhancement measures scar transmurality and adds function and anatomy. The best choice balances the specific question (metabolic viability vs scar burden), availability, and image quality.

The decision in one place

To identify hibernating myocardium, look for a flow–metabolism mismatch on FDG-PET (the reference standard: reduced perfusion with retained FDG). Where PET is unavailable, use thallium redistribution/reinjection or nitrate sestamibi SPECT; where scar characterization and function matter, use LGE-MRI (subendocardial/limited scar predicts recovery; near-transmural scar does not). All target the same clinical decision: whether revascularization is likely to recover contractile function.

Head-to-head

How to sequence

By scenario:

• Ischemic cardiomyopathy, revascularization being considered, question is hibernation: FDG-PET perfusion/metabolism — the mismatch pattern is the most established predictor of functional recovery.
• PET unavailable: thallium redistribution/reinjection or nitrate-augmented sestamibi SPECT.
• Need scar burden, function, and anatomy in one study: LGE-MRI — transmural extent of enhancement predicts recovery (subendocardial scar recovers; transmural does not), and it simultaneously quantifies EF and volumes.
• Contractile reserve question / no access to PET or MRI: dobutamine echo.

Interpreting the patterns

The unifying logic is flow vs viability. On FDG-PET, matched defects (reduced perfusion and reduced FDG) are scar; mismatched defects (reduced perfusion but preserved FDG) are hibernating and the target for revascularization. On MRI, transmurality of late enhancement inversely predicts recovery — the less transmural the scar, the more likely function returns. SPECT thallium redistribution reflects viable but hypoperfused cells reaccumulating tracer over time.

Pitfalls in selection

• Metabolic preparation is decisive for FDG cardiac PET: unlike suppression for inflammation studies, viability imaging drives FDG into myocytes (glucose loading ± insulin, or a glucose–insulin–potassium protocol); poor prep degrades interpretation.
• Clinical benefit of viability-guided revascularization is debated — imaging identifies viable myocardium, but revascularization decisions integrate symptoms, anatomy, and risk, not viability alone.
• Balanced/severe multivessel disease can mask perfusion gradients; integrate quantitation and clinical context.

Bottom line

FDG-PET mismatch is the reference test for hibernating myocardium; thallium/nitrate-sestamibi SPECT are the available alternatives; LGE-MRI characterizes scar transmurality with function and anatomy — all answering whether revascularization will recover contraction.

Self-Check

Key References

• ASNC/SNMMI guidance on FDG PET myocardial viability imaging and metabolic preparation.
• Comparative literature on FDG-PET mismatch, thallium redistribution, and LGE-MRI transmurality for predicting recovery; trials examining viability-guided revascularization.